{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"127"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"To determine the number of participants on each arm who received the surgery planned at randomization.","groups":[{"description":"Within 17 days (preferably within 14 days) days after IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.\n\nBiospecimen Collection: Undergo collection of blood\n\nComputed Tomography: Undergo CT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPembrolizumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"OG000","title":"Arm I (Adjuvant Pembrolizumab)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.\n\nBiospecimen Collection: Undergo collection of blood\n\nComputed Tomography: Undergo CT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPembrolizumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"OG001","title":"Arm II (Adjuvant and Neoadjuvant Pembrolizumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2.5 years","title":"Number of Participants Receiving Surgery","type":"SECONDARY","unitOfMeasure":"Participants"}